CLU and prostate carcinoma: Quantitative reverse transcriptase PCR (Q-PCR) and immunohistochemistry (IHC) showed a very efficient dose dependent inhibition of clusterin mRNA (>90% at the maximum dose) and protein (complete suppression in 57% of cells at the maximum dose) in prostate cancer tissue.